Abstract
In deceased donors, Ischemia/Reperfusion Injury (IRI) is an important cause of allograft dysfunction. Prolonged cold and warm ischemia time leads to a high risk of early post-transplant complications, including acute and chronic rejection. Ischemia not only up-regulates inflammatory cytokines and chemokines, but also enhances the expression of MHC-class II and adhesion molecules on epithelial and dendritic cells. Moreover, the Danger Associated Molecular Patterns (DAMPs) released from stressed or dying cells, not only cause or amplify tissue inflammation and trigger tissue repair in response to IRI, but also act as adjuvants that enhance DC maturation and potentiate the adaptive immune response. In this review, we will also discuss about whether donor or recipient DCs are more important in the process of ischemia enhanced acute rejection.
Keywords: Dendritic cells, Kidney transplantation, Allograft rejection, Ischemia/reperfusion injury, APC, CTLs.
Current Gene Therapy
Title:How Do Dendritic Cells Play the Role in Ischemia/Reperfusion Triggered Kidney Allograft Rejection
Volume: 17 Issue: 6
Author(s): Songjie Cai*, Naotsugu Ichimaru and Shiro Takahara*
Affiliation:
- Department of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Osaka,Japan
- Department of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Osaka,Japan
Keywords: Dendritic cells, Kidney transplantation, Allograft rejection, Ischemia/reperfusion injury, APC, CTLs.
Abstract: In deceased donors, Ischemia/Reperfusion Injury (IRI) is an important cause of allograft dysfunction. Prolonged cold and warm ischemia time leads to a high risk of early post-transplant complications, including acute and chronic rejection. Ischemia not only up-regulates inflammatory cytokines and chemokines, but also enhances the expression of MHC-class II and adhesion molecules on epithelial and dendritic cells. Moreover, the Danger Associated Molecular Patterns (DAMPs) released from stressed or dying cells, not only cause or amplify tissue inflammation and trigger tissue repair in response to IRI, but also act as adjuvants that enhance DC maturation and potentiate the adaptive immune response. In this review, we will also discuss about whether donor or recipient DCs are more important in the process of ischemia enhanced acute rejection.
Export Options
About this article
Cite this article as:
Cai Songjie *, Ichimaru Naotsugu and Takahara Shiro *, How Do Dendritic Cells Play the Role in Ischemia/Reperfusion Triggered Kidney Allograft Rejection, Current Gene Therapy 2017; 17 (6) . https://dx.doi.org/10.2174/1566523218666180214095956
DOI https://dx.doi.org/10.2174/1566523218666180214095956 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Current Pharmaceutical Design Platelet-neutrophil Interactions as a Target for Prevention and Treatment of Transfusion- related Acute Lung Injury
Current Pharmaceutical Design Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology
Current Pharmaceutical Design Genipin Inhibits the Induction of Inducible Nitric Oxide Synthase Through the Inhibition of NF-κB Activation in Rat Hepatocytes
Drug Metabolism Letters Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration
Current Neuropharmacology Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) Effects of Nicotine on the Cardiovascular System
Vascular Disease Prevention (Discontinued) IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Renal-Protective Activity of Dried Gel of <i>Aloe barbadensis</i> (Elwa) on Gentamicin- Induced Nephrotoxicity in Albino Rats
Current Traditional Medicine Nano-based Drug Delivery System Enhances the Oral Absorption of Lipophilic Drugs with Extensive Presystemic Metabolism
Current Drug Metabolism Role of Dietary Polyphenols in Attenuating Brain Edema and Cell Swelling in Cerebral Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Propofol Pharmacokinetics in Patients with Obstructive Jaundice
Current Drug Delivery Caveolin-1: A Promising Therapeutic Target for Diverse Diseases
Current Molecular Pharmacology Importance of Aquaporins in the Physiopathology of Brain Edema
Current Pharmaceutical Design Ischemic Neuronal Damage
Current Pharmaceutical Design Modulation of Apoptosis in Acute Ischemic Stroke as Treatment Challenges
Current Immunology Reviews (Discontinued) Aldehyde Dehydrogenase-2 Roles in Ischemic Cardiovascular Disease
Current Drug Targets Differences in Relative Levels of 88 microRNAs in Various Regions of the Normal Adult Human Brain
MicroRNA Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets The role of NADPH Oxidase in Vascular Disease – Hypertension, Atherosclerosis & Stroke
Current Pharmaceutical Design